In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The closing price of Akero Therapeutics Inc (NASDAQ: AKRO) was $46.41 for the day, up 2.63% from the previous closing price of $45.22. In other words, the price has increased by $2.63 from its previous closing price. On the day, 0.86 million shares were traded. AKRO stock price reached its highest trading level at $46.5 during the session, while it also had its lowest trading level at $44.53.
Ratios:
Our analysis of AKRO’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 12.66 and its Current Ratio is at 12.66. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.02.
On August 04, 2025, TD Cowen started tracking the stock assigning a Buy rating and target price of $76. BofA Securities Upgraded its Neutral to Buy on January 30, 2025, whereas the target price for the stock was revised from $35 to $63.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 11 ’25 when Young Jonathan sold 586 shares for $43.02 per share. The transaction valued at 25,210 led to the insider holds 196,898 shares of the business.
Yale Catriona sold 659 shares of AKRO for $28,350 on Sep 11 ’25. The Chief Development Officer now owns 90,829 shares after completing the transaction at $43.02 per share. On Sep 11 ’25, another insider, White William Richard, who serves as the Chief Financial Officer of the company, sold 659 shares for $43.02 each. As a result, the insider received 28,350 and left with 57,752 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AKRO now has a Market Capitalization of 3712288256 and an Enterprise Value of 3006313216.
Stock Price History:
The Beta on a monthly basis for AKRO is -0.30, which has changed by 0.6545454 over the last 52 weeks, in comparison to a change of 0.1675967 over the same period for the S&P500. Over the past 52 weeks, AKRO has reached a high of $58.40, while it has fallen to a 52-week low of $21.34. The 50-Day Moving Average of the stock is -3.44%, while the 200-Day Moving Average is calculated to be 5.91%.
Shares Statistics:
AKRO traded an average of 1.21M shares per day over the past three months and 1413540 shares per day over the past ten days. A total of 79.92M shares are outstanding, with a floating share count of 70.72M. Insiders hold about 11.59% of the company’s shares, while institutions hold 107.10% stake in the company. Shares short for AKRO as of 1756425600 were 8889091 with a Short Ratio of 7.37, compared to 1753920000 on 8121294. Therefore, it implies a Short% of Shares Outstanding of 8889091 and a Short% of Float of 11.4300005.
Earnings Estimates
The market rating for Akero Therapeutics Inc (AKRO) is a result of the insights provided by 8.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.97, with high estimates of -$0.92 and low estimates of -$1.06.
Analysts are recommending an EPS of between -$3.58 and -$4.03 for the fiscal current year, implying an average EPS of -$3.72. EPS for the following year is -$4.24, with 7.0 analysts recommending between -$4.01 and -$4.9.
